St. Petersburg Research Institute of Vaccines and Sera

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine

Phase 2

Completed

Conditions: Vaccine Reaction
Vaccination; Infection
Influenza, Human
Influenza Viral Infections
Influenza

Interventions: Biological: Influenza vaccine [inactivated]

First Posted Date: 2023-05-22

Last Posted Date: 2023-05-22

Lead Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Target Recruit Count: 450

Registration Number: NCT05869201

Locations: 🇷🇺
Eco-Safety Scientific Research and Development Center Limited Liability Company (Eco-Safety Scientific Research and Development Center LLC), Saint-Petersburg, Russian Federation
🇷🇺
Federation (FSBEI of Higher Education "E. A. Wagner PSMU" of the of the Ministry of Health of the Russian Federation), Perm, Russian Federation
🇷🇺
Federally Funded Healthcare Institution Primary Healthcare Unit No. 163,of Federal Medical and Biologic Agency (FFHI PHU No. 163, FMBA of Russia), Kol'tsovo, Novosibirsk Region, Russian Federation

and more 2 locations

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

Phase 3

Recruiting

Conditions: Influenza
Vaccine Reaction
Influenza, Human
Influenza Viral Infections

Interventions: Biological: Influenza vaccine [inactivated]

First Posted Date: 2023-02-22

Last Posted Date: 2023-08-30

Lead Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Target Recruit Count: 948

Registration Number: NCT05739474

Locations: 🇷🇺
State Budgetary Healthcare Institution of the Perm Territory "City Children's Clinical Clinic No. 5", Perm, Russian Federation
🇷🇺
Llc "Olla-Med", Moscow, Russian Federation
🇷🇺
LLC "Professorskaya Clinica", Perm, Russian Federation

and more 4 locations

Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older

Phase 2

Active, not recruiting

Conditions: COVID-19
Coronavirus Infections
COVID-19 Respiratory Infection
Respiratory Tract Infections

Interventions: Biological: Subunit recombinant vaccine for the prevention of coronavirus infection
Biological: Placebo

First Posted Date: 2023-02-13

Last Posted Date: 2023-08-30

Lead Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Target Recruit Count: 16304

Registration Number: NCT05726084

Locations: 🇷🇺
Limited Liability Company "OLLA-MED", Moscow, Russian Federation
🇷🇺
State budgetary health care institution of the city of Moscow "City Clinical Hospital No. 24 of the Department of Health of the City of Moscow", Moscow, Russian Federation
🇷🇺
Limited Liability Company "Meditsinskiy Diagnosticheskiy Tsentr", Yaroslavl, Russian Federation

and more 3 locations

Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old

Phase 3

Completed

Conditions: Vaccines
Influenza, Human
Vaccination; Infection

Interventions: Biological: Flu-M, Inactivated split influenza vaccine 0.25 mL
Biological: Vaxigrip, Inactivated split influenza vaccine 0.25 mL
Biological: Flu-M, Inactivated split influenza vaccine 0.5 mL
Biological: Vaxigrip, Inactivated split influenza vaccine 0.5 mL

First Posted Date: 2022-07-22

Last Posted Date: 2022-07-22

Lead Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Target Recruit Count: 1066

Registration Number: NCT05470582

Locations: 🇷🇺
St. Petersburg State Budgetary Institution of Health Care "Children's City Polyclinic No. 45" of the Nevsky District, Saint Petersburg, Russian Federation
🇷🇺
LLC "Energiya zdorov'ya", Saint Petersburg, Russian Federation

Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women

Phase 3

Completed

Conditions: Influenza, Human
Vaccines
Vaccination; Infection

Interventions: Biological: Flu-M, Inactivated split influenza vaccine
Biological: Ultrix®, Inactivated Split Influenza Vaccine

First Posted Date: 2022-07-14

Last Posted Date: 2022-07-14

Lead Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Target Recruit Count: 207

Registration Number: NCT05457894

Locations: 🇷🇺
Municipal Budgetary Institution "Central City Hospital No.7", Ekaterinburg, Russian Federation
🇷🇺
KOROLEV MEDICINE Limited Liability Company, Saint Petersburg, Russian Federation
🇷🇺
Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation, Barnaul, Altai Territory, Russian Federation

and more 2 locations

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b

Phase 1

Completed

Conditions: Haemophilus Influenzae Infection
Vaccines

Interventions: Biological: Placebo
Biological: Vaccine for the prevention of infections caused by Haemophilus influenza type b

First Posted Date: 2022-06-02

Last Posted Date: 2022-06-02

Lead Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Target Recruit Count: 60

Registration Number: NCT05401305

Locations: 🇷🇺
Federally Funded Healthcare Institution Primary Healthcare Unit No.163, Federal Medical-Biological Agency (FFHI PHU No.163, FMBA of Russia), Koltsovo, Russian Federation

Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers

Phase 1

Completed

Conditions: Tuberculosis
Skin Tests

Interventions: Diagnostic Test: Placebo
Diagnostic Test: Mycobacterial recombinant allergens 0.2 μg
Diagnostic Test: Mycobacterial recombinant allergens 0.1 μg

First Posted Date: 2022-06-01

Last Posted Date: 2022-06-01

Lead Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Target Recruit Count: 75

Registration Number: NCT05398562

Locations: 🇷🇺
Limited Liability Company "Scientific Research Center Eco-Safety", Saint Petersburg, Russian Federation

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Flu-M [Inactivated split influenza vaccine]
Biological: Inactivated Split Influenza Vaccine

First Posted Date: 2022-04-08

Last Posted Date: 2022-04-08

Lead Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Target Recruit Count: 600

Registration Number: NCT05317767

Locations: 🇷🇺
Perm State Medical University named after Academician E. A. Wagner, Perm, Russian Federation
🇷🇺
LLC "Meditsinskie Tehnologii", Saint Petersburg, Russian Federation

Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years

Phase 3

Completed

Conditions: Influenza
Flu, Human

Interventions: Biological: Flu-M [inactivated split influenza vaccine] without preservative
Biological: Flu-M [inactivated split influenza vaccine] with preservative

First Posted Date: 2022-04-05

Last Posted Date: 2022-04-05

Lead Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Target Recruit Count: 654

Registration Number: NCT05312294

Locations: 🇷🇺
State Autonomous Health Institution "Engels City Clinical Hospital No1", Engels, Russian Federation
🇷🇺
Limited Liability Company "Clinika Zvezdnaya", Saint Petersburg, Russian Federation
🇷🇺
Limited Liability Company "MEDICINSKAYA CLINIKA", Saint Petersburg, Russian Federation

and more 5 locations

Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Ultrix [Inactivated split influenza vaccine]
Biological: Flu-M Tetra [Inactivated split influenza vaccine] w/p
Biological: Flu-M Tetra [Inactivated split influenza vaccine] w/o/p

First Posted Date: 2022-04-04

Last Posted Date: 2022-11-08

Lead Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Target Recruit Count: 633

Registration Number: NCT05308212

Locations: 🇷🇺
Piramida Limited Liability Company, Saint Petersburg, Russian Federation
🇷🇺
Saint Petersburg State Budgetary Healthcare Institution "State Polyclinic No. 43", Saint Petersburg, Russian Federation
🇷🇺
Limited Liability Company Professorskaya Clinica, Perm, Russian Federation

and more 8 locations

Home Terms & Conditions Privacy Policy